2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149536
    TWIK-1/TREK-1-IN-1 1440532-30-8 98%
    TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects.
    TWIK-1/TREK-1-IN-1
  • HY-149537
    TWIK-1/TREK-1-IN-2 1440532-32-0 98%
    TWIK-1/TREK-1-IN-2 (Compound 2g) is a TWIK-1/TREK-1 inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant.
    TWIK-1/TREK-1-IN-2
  • HY-149538
    TWIK-1/TREK-1-IN-3 1440532-33-1 99.61%
    TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects.
    TWIK-1/TREK-1-IN-3
  • HY-149542
    GSK-3β inhibitor 15 98%
    GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC50: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD).
    GSK-3β inhibitor 15
  • HY-149548
    2,3-Dinor-8-iso prostaglandin F1α 221664-04-6 98%
    2,3-Dinor-8-iso prostaglandin F1α is an isoprostanoid that can be used as a biomarker to assess psychological stress.
    2,3-Dinor-8-iso prostaglandin F1α
  • HY-149582
    Aβ-IN-7 98%
    Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM.
    Aβ-IN-7
  • HY-149583
    Aβ-IN-8 98%
    Aβ-IN-8 (compound 7e) is a potent inhibitor of the Aβ aggregation.
    Aβ-IN-8
  • HY-149608
    Nurr1 agonist 5 3033875-32-7 98%
    Nurr1 agonist 5 (compound 5o) is a neuroprotective transcription factor Nurr1 agonist with a Kd of 0.5 μM and an EC50 of 3 μM.
    Nurr1 agonist 5
  • HY-149654
    FAAH/cPLA2α-IN-1 1696401-38-3 98%
    FAAH/cPLA2α-IN-1 is a dual inhibitor of FAAH and cPLA2α with IC50s of 32 and 47 nM, respectively.
    FAAH/cPLA2α-IN-1
  • HY-149702
    M1/M4 muscarinic agonist 1 98%
    M1/M4 muscarinic agonist 1 (compound 41) is a selective muscarinic M4/M1 agonist with EC50 values of 14 and 55 nM for M4 and M1, respectively. M1/M4 muscarinic agonist 1 can be used for research on mental diseases, such as schizophrenia, delusional disorder, etc.
    M1/M4 muscarinic agonist 1
  • HY-149704
    M1/M2/M4 muscarinic agonist 1 2640109-42-6 98%
    M1/M2/M4 muscarinic agonist 1 (Compound 42) is a muscarinic M4/M1/M2 agonist with EC50 values of 6.5, 26 and 210 nM for M4/M1/M2, respectively. M1/M2/M4 muscarinic agonist 1 can be used for research on mental diseases, such as schizophrenia, delusion, etc.
    M1/M2/M4 muscarinic agonist 1
  • HY-149725
    proMMP-9 selective inhibitor-1 98%
    proMMP-9 selective inhibitor-1 (compound 33) is a highly potent and selective inhibitor of proMMP-9 activation.
    proMMP-9 selective inhibitor-1
  • HY-149731
    M1/M2/M4 muscarinic agonist 2 98%
    M1/M2/M4 muscarinic agonist 2 (compound 43) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 30 nM, 200 nM and 6.2 nM, respectively.
    M1/M2/M4 muscarinic agonist 2
  • HY-149732
    M1/M4 muscarinic agonist 3 2640109-30-2 98%
    M1/M4 muscarinic agonist 3 (compound 44) is a muscarinic mAChR M1/M4 agonist with EC50s of 31 nM and 9.3 nM, respectively.
    M1/M4 muscarinic agonist 3
  • HY-149733
    M1/M2/M4 muscarinic agonist 3 2640109-28-8 98%
    M1/M2/M4 muscarinic agonist 3 (compound 45) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 3.2 nM, 32 nM and 1.7 nM, respectively.
    M1/M2/M4 muscarinic agonist 3
  • HY-149764
    Aβ42 agonist-2 6314-40-5 99.92%
    Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells.
    Aβ42 agonist-2
  • HY-149772
    Ciguatoxin CTX 3C 148471-85-6 98%
    Ciguatoxin CTX 3C, an immunizing and heterologous hapten, induces a rapid imbalance in neuronal excitability.
    Ciguatoxin CTX 3C
  • HY-149776
    RGH-560 2408799-43-7 98%
    RGH-560 (compound 53) shows highly advanced α7 nAChR positive modulator properties and favorable physicochemical features. RGH-560 has robust procognitive in vivo potential. RGH-560 can be used to study Scopolamine (HY-N0296) -induced amnesia in mice.
    RGH-560
  • HY-149817
    AChE-IN-29 98%
    AChE-IN-29, 3-OH pyrrolidine derivative, is an cholinesterase (ChE) inhibitor. AChE-IN-29 has cholinesterase inhibitory activity for hAChE, eeAChE and eqBChE with IC50 values of 0.25 μM, 0.23 μM and 0.72 μM, respectively. AChE-IN-29 can be used for the research of Alzheimer's disease.
    AChE-IN-29
  • HY-149820
    MAO-B-IN-22 2902600-76-2 98%
    MAO-B-IN-22 (compound 6h) is a potent MAO-B inhibitor with an IC50 of 0.014 μM. MAO-B-IN-22 has high antioxidant activity, good metal chelating ability, proper BBB permeability and significant neuroprotective effect.
    MAO-B-IN-22
Cat. No. Product Name / Synonyms Application Reactivity